News and Events Joni Henderson 9/30/24 Joni Henderson 9/30/24 C2N Diagnostics Receives $15 Million Program Related Investment from GHR Foundation to Develop Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease Read More Joni Henderson 9/25/24 Joni Henderson 9/25/24 C2N Receives Funding from Diagnostics Accelerator to Develop a Decentralized Clinical Mass Spectrometry Solution to Enable High-Performance Alzheimer’s Disease Testing Worldwide Read More Joni Henderson 8/6/24 Joni Henderson 8/6/24 C2N Diagnostics and Unilabs Announce Global Partnership, Bringing Together Innovation Leaders in Diagnostics and Laboratory Medicine to Advance Brain Health Read More Joni Henderson 7/28/24 Joni Henderson 7/28/24 JAMA Publishes Landmark Clinical Study Showing C2N Diagnostics’ PrecivityAD2™ Blood Test Markedly Improves Accuracy of AD Diagnosis in Both Primary Care and Specialized Memory Care Read More Joni Henderson 7/2/24 Joni Henderson 7/2/24 C2N Diagnostics Says FDA’s Approval of Donanemab Highlights Its Role in Helping to Determine Alzheimer’s Disease Pathology Read More Joni Henderson 6/26/24 Joni Henderson 6/26/24 C2N’s Precivity™ Tests are Now Offered Through Mayo Clinic Laboratories Read More Joni Henderson 4/26/24 Joni Henderson 4/26/24 C₂N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing forAlzheimer’s Disease and Brain Research Market Read More Joni Henderson 3/31/24 Joni Henderson 3/31/24 Study Finds C₂N Diagnostics’ PrecivityAD® Blood Test Provides Opportunities for Robust Cost Savings in the Evaluation of Patients with Cognitive Impairment Read More Joni Henderson 3/18/24 Joni Henderson 3/18/24 New Research Shows the PrecivityAD2™ Blood Test Has High Accuracy Compared to Amyloid PET Scans in Individuals with Cognitive Impairment Read More Joni Henderson 3/6/24 Joni Henderson 3/6/24 C₂N Diagnostics, LLC Announces Investment From Eisai Inc. Read More Joni Henderson 11/16/23 Joni Henderson 11/16/23 Researchers Identify New Cost Savings and Accuracy of C₂N Diagnostics’ Blood Tests to Enable Healthcare Providers to Better Identify Alzheimer’s Disease Read More Joni Henderson 11/7/23 Joni Henderson 11/7/23 New Research Shows High Accuracy of Precivity™ Blood Biomarkers in the Evaluation of Brain Amyloid in Pre-Clinical Alzheimer's Disease Read More Joni Henderson 10/25/23 Joni Henderson 10/25/23 C₂N Diagnostics Introduces Next-Generation Fluid Biomarker to the Field of Alzheimer’s Disease: Test to Help Researchers Track Neurofibrillary “Tau” Tangle Pathology Read More Joni Henderson 9/21/23 Joni Henderson 9/21/23 On World Alzheimer’s Day, C₂N Diagnostics’ PrecivityAD2™ Blood Test Expands Reach Read More Joni Henderson 8/17/23 Joni Henderson 8/17/23 C₂N Diagnostics Releases the PrecivityAD2™ Blood Test for Clinical Care, a Robust Assay with High Concordance to Amyloid PET and CSF Read More Joni Henderson 8/8/23 Joni Henderson 8/8/23 Real-World Evidence Shows Healthcare Providers Use C₂N Diagnostics’ PrecivityAD® Blood Test to Help Affirm Alzheimer’s Disease Diagnosis and Change Drug Treatment Decisions Read More Joni Henderson 8/2/23 Joni Henderson 8/2/23 Alzheimer’s Disease Community Benefits as C₂N Diagnostics’ Precivity™-Related Blood Biomarkers Demonstrate Robust Effectiveness, Set New Performance Standard Read More Tim West 7/11/23 Tim West 7/11/23 C₂N Diagnostics, Used in Clinical Trials for LEQEMBI™ for Alzheimer’s Disease Treatment, Is Poised to Support Medical Community in Next Steps Read More Joni Henderson 4/24/23 Joni Henderson 4/24/23 C₂N Diagnostics, Building on Recent Achievements, Bolsters Executive Team as It Prepares for Commercial Expansion Read More Joni Henderson 4/4/23 Joni Henderson 4/4/23 C₂N Diagnostics’ Precivity-Related Blood Biomarkers Shown to Improve Diagnostic Accuracy and Future Risk Prediction of Alzheimer’s Disease in Two Studies Presented at AD/PD 2023 Read More Older Posts Subscribe to our newsletter. Sign up with your email address to receive news and updates. First Name Last Name Email Address Sign Up Thank you!
Joni Henderson 9/30/24 Joni Henderson 9/30/24 C2N Diagnostics Receives $15 Million Program Related Investment from GHR Foundation to Develop Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease Read More
Joni Henderson 9/25/24 Joni Henderson 9/25/24 C2N Receives Funding from Diagnostics Accelerator to Develop a Decentralized Clinical Mass Spectrometry Solution to Enable High-Performance Alzheimer’s Disease Testing Worldwide Read More
Joni Henderson 8/6/24 Joni Henderson 8/6/24 C2N Diagnostics and Unilabs Announce Global Partnership, Bringing Together Innovation Leaders in Diagnostics and Laboratory Medicine to Advance Brain Health Read More
Joni Henderson 7/28/24 Joni Henderson 7/28/24 JAMA Publishes Landmark Clinical Study Showing C2N Diagnostics’ PrecivityAD2™ Blood Test Markedly Improves Accuracy of AD Diagnosis in Both Primary Care and Specialized Memory Care Read More
Joni Henderson 7/2/24 Joni Henderson 7/2/24 C2N Diagnostics Says FDA’s Approval of Donanemab Highlights Its Role in Helping to Determine Alzheimer’s Disease Pathology Read More
Joni Henderson 6/26/24 Joni Henderson 6/26/24 C2N’s Precivity™ Tests are Now Offered Through Mayo Clinic Laboratories Read More
Joni Henderson 4/26/24 Joni Henderson 4/26/24 C₂N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing forAlzheimer’s Disease and Brain Research Market Read More
Joni Henderson 3/31/24 Joni Henderson 3/31/24 Study Finds C₂N Diagnostics’ PrecivityAD® Blood Test Provides Opportunities for Robust Cost Savings in the Evaluation of Patients with Cognitive Impairment Read More
Joni Henderson 3/18/24 Joni Henderson 3/18/24 New Research Shows the PrecivityAD2™ Blood Test Has High Accuracy Compared to Amyloid PET Scans in Individuals with Cognitive Impairment Read More
Joni Henderson 3/6/24 Joni Henderson 3/6/24 C₂N Diagnostics, LLC Announces Investment From Eisai Inc. Read More
Joni Henderson 11/16/23 Joni Henderson 11/16/23 Researchers Identify New Cost Savings and Accuracy of C₂N Diagnostics’ Blood Tests to Enable Healthcare Providers to Better Identify Alzheimer’s Disease Read More
Joni Henderson 11/7/23 Joni Henderson 11/7/23 New Research Shows High Accuracy of Precivity™ Blood Biomarkers in the Evaluation of Brain Amyloid in Pre-Clinical Alzheimer's Disease Read More
Joni Henderson 10/25/23 Joni Henderson 10/25/23 C₂N Diagnostics Introduces Next-Generation Fluid Biomarker to the Field of Alzheimer’s Disease: Test to Help Researchers Track Neurofibrillary “Tau” Tangle Pathology Read More
Joni Henderson 9/21/23 Joni Henderson 9/21/23 On World Alzheimer’s Day, C₂N Diagnostics’ PrecivityAD2™ Blood Test Expands Reach Read More
Joni Henderson 8/17/23 Joni Henderson 8/17/23 C₂N Diagnostics Releases the PrecivityAD2™ Blood Test for Clinical Care, a Robust Assay with High Concordance to Amyloid PET and CSF Read More
Joni Henderson 8/8/23 Joni Henderson 8/8/23 Real-World Evidence Shows Healthcare Providers Use C₂N Diagnostics’ PrecivityAD® Blood Test to Help Affirm Alzheimer’s Disease Diagnosis and Change Drug Treatment Decisions Read More
Joni Henderson 8/2/23 Joni Henderson 8/2/23 Alzheimer’s Disease Community Benefits as C₂N Diagnostics’ Precivity™-Related Blood Biomarkers Demonstrate Robust Effectiveness, Set New Performance Standard Read More
Tim West 7/11/23 Tim West 7/11/23 C₂N Diagnostics, Used in Clinical Trials for LEQEMBI™ for Alzheimer’s Disease Treatment, Is Poised to Support Medical Community in Next Steps Read More
Joni Henderson 4/24/23 Joni Henderson 4/24/23 C₂N Diagnostics, Building on Recent Achievements, Bolsters Executive Team as It Prepares for Commercial Expansion Read More
Joni Henderson 4/4/23 Joni Henderson 4/4/23 C₂N Diagnostics’ Precivity-Related Blood Biomarkers Shown to Improve Diagnostic Accuracy and Future Risk Prediction of Alzheimer’s Disease in Two Studies Presented at AD/PD 2023 Read More
